Two significant programs that invested in research on diabetes, dementia, obesity and kidney disease have ended since the start of the Trump administration.
NYT > U.S. > Politics
Parkland Strongly Reaffirms Board’s Capability to Lead Strategic Review and Maximize Shareholder Value
Publishes Presentation Refuting Simpson Oil’s Misleading Claims Encourages Shareholders to Continue Voting ONLY on the…
